We have reported our negative results as: "Preliminary results indicate no differences in biochemical or functional measures of efficacy or safety with chronic SDG consumption".
We include and then elaborate this statement "Oxidative stress and inflammation are associated with a number of chronic diseases common among the older adults " our rationale is the age of the subjects in this new study: "...most studies have focused on adults less than 60 years of age [9] . Consequently, limited information is available in seniors and studies are necessary to confirm their safety and efficacy in this 'subpopulation' of older adults.
We have the hypothesis: "The hypothesis being tested is that consumption of SDG, in persons with adequate vitamin D status, will decrease oxidative stress and associated inflammation and improve secondary measures of function by six months."
We write "A 24-week double blind randomized clinical trial was conducted ". Then we explain the control and intervention group assignments.
We had no changes, however we did experience low enrolment.
Not relevant.
We describe eligibility in terms of exclusion criteria: "Exclusion criteria included: age below 60 or above 80 years at initiation of the study; living in long term care (nursing) homes; individuals at risk of hypotension or with symptomatic hypotension; fasting hypoglycemia; unstable diabetes, or diabetics taking insulin; current cancer or diagnosed with cancer in the past 2 years; women with an immediate family history or personal history of breast cancer or ovarian cancer; significant liver or other gastrointestinal disorder including inflammatory bowel disease; significant kidney disorder;
No subject was required to use internet.
Recruitment is described:"Recruitment of participants was undertaken using posters and newspaper advertisements. Study posters were displayed in local hospitals, on University of Saskatchewan campus, and several senior residences. Contact information of the study coordinator was provided. Interested volunteers called the study coordinator, who reviewed inclusion and exclusion criteria over the phone. Volunteers who met the criteria were requested to visit the study coordinator's office... "
Information was given as consent form which we are not publishing as it is very lengthy. We have summarized what each subject would do over the 6 months as a Figure 2 and what each subjects would do on a testing day as Figure 3 .
The setting was a single city in Canada, using a single clinical site. "After recruiting new participants, a study number was assigned and participants were given the map of the Saskatchewan Centre for Patient-Oriented Research (SCPOR) facility. As well, participants were given the toilet hat and instructions to collect fecal samples for baseline. All study visits took place at the SCPOR facility located at City Hospital in Saskatoon Canada" our intervention is repeatable as sufficient information is provided: "(1) Intervention: 1.6 grams of SDG-enriched food grade flaxseed lignan complex Beneflax® containing 600 mg SDG, plus 1,000 IU Vitamin D3; (2) Placebo Control: 0.6 grams whey protein (similar in volume to the intervention compound) plus 1,000 IU Vitamin D3. Vitamin D tablets were provided separately. As the daily dose could not be delivered in one packet, instructions were to consume two packets per day. Each packet contained 0.8 g of Beneflax® or 0.3 g of placebo (a volume equivalent to
We state that all questionnaires and other tests "were measured by research staff using standard procedures".
No instructional, behavioral or persuasive strategies used.
We ensured doses were followed by providing product in large amounts in easy to store packets: "The packets of Beneflax® and whey were prepared by the research staff following the safe food preparation procedures. Study compounds were sent to a designated pharmacy where the pharmacist oversaw the dispensing of products into packets, which were labelled and packaged into 12 week supplies in child-proof amber containers with instructions to store in the fridge. "
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This was not an eHealth intervention.
Yes we have defined these. "Primary outcome measures were those of efficacy and safety of 6-month administration of 600 mg SDG per day to healthy older adults. We included the reporting of clinical adverse signs and symptoms, vital signs, serum clinical chemistry, and hematology parameters. The secondary outcome measures were to determine the effects of flaxseed lignan supplementation on biomarkers of inflammation, risk factors of cardiovascular disease, functional (i.e. quality of life) indicators, and
No online questionnaires.
CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS6... Dose is described: "As the daily dose could not be delivered in one packet, instructions were to consume two packets per day. Each packet contained 0.8 g of Beneflax® or 0.3 g of placebo (a volume equivalent to the volume of Beneflax® given). The product was taken at the same time each day (example: always with breakfast or always with dinner). Either compound (lignan or whey powder) could be added to a tablespoon of applesauce or equivalent food. "
We did not ask for feedback. When subjects came in for testing they chatted with staff.
No changes.
A calculated sample size to meet the primary objective of a change in blood pressure wit the dose provided was 30 per group. We did not meet this recruitment goal.
No. Our study ran the full 6 months.
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22-Nov-16 5:41 PM Yes, we used randomization: "Beneflax® or placebo was administered in a double-blind fashion. Only the pharmacist, who used a computer-aided randomization system, knew group assignments; all personnel performing the data collection and analysis were blind to group assignment. The pharmacist kept a secure copy of the randomization codes during the study. "
We did not make any subgrouping.
All were blinded except pharmacist: "Only the pharmacist, who used a computer-aided randomization system, knew group assignments; all personnel performing the data collection and analysis were blind to group assignment. The pharmacist kept a secure copy of the randomization codes during the study. "
we used a placebo that was not identical to the active ingredient. However, subjects were not shown the other treatment. All were interested to know, after unblinding, what their treatment was.
Intervention compounds were not identical and had a slight colour difference. They were "The packets of [flax lignan] Beneflax® and whey". "
Consent was paper-based.
We describe "Adverse Events Monitoring" as follows: "Adverse events were recorded throughout the study. An "adverse event" was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product. All research team members in contact with participants were responsible for noting adverse events, which were reported by the participant. Participants were advised to communicate the adverse event at the time of occurrence to the Physician Responsible for Trial Site Medical Decisions Not applicable. Care, per se, was not provided. however in terms of enrolment, 19 were in Intervention and 13 were in Control groups.
We do not have a consort flow diagram in our protocol paper. We had 2 dropouts just after consenting but before any testing occurred. This is our description: "There were 34 potential participants (16 females, 18 males) who met exclusion criteria and who consented to be in the study; however, after consenting two participants, one male and one female, withdrew. The 32 participants remaining in the study came to all four visits except one participant.. "
We had no attrition.
